In vitro modulation of natural killer cell activity in non-Hodgkin's lymphoma patients after therapy
β Scribed by Bela A. Mehta; Mangesh N. Satam; Suresh H. Advani; Jayshree J. Nadkarni
- Book ID
- 104660389
- Publisher
- Springer-Verlag
- Year
- 1989
- Tongue
- English
- Weight
- 506 KB
- Volume
- 28
- Category
- Article
- ISSN
- 0340-7004
No coin nor oath required. For personal study only.
β¦ Synopsis
The depressed natural killer (NK) activity, antibody-dependent cellular cytotoxicity (ADCC) and N K cytotoxic factor cytotoxicity in untreated non-Hodgkin's lymphoma patients were found to be elevated after chemotherapy. In vitro treatment of the effector N K cells with interferon a could augment the NK activity in normal subjects and treated patients to a comparable degree. Chemotherapy mainly affected the post-binding events in the NK cytotoxic process by causing an increase in the active killing potential of the N K cells. This study provides a better understanding of changes in the NK cytotoxic mechanism in non-Hodgkin's lymphoma patients and the role of interferon in this process.
production in untreated cases of NHL [7]. In this study we show that the NK, ADCC and AK cytotoxicities were restored to almost normal levels in the NHL patients after completion of therapy. The post-binding events in the NK-cell-mediated cytotoxic mechanism were more depressed in the untreated cases, becoming elevated after treatment. When the lymphocytes were exposed to leukocyte interferon (IFN-c 0 in vitro, the augmentation of NK activity was restored to almost normal levels in the treated patients. This study provides a further insight into the alterations in the NK-cell-mediated cytotoxic mechanism in cases of NHL and reiterates a therapeutic role for interferon in these patients.
π SIMILAR VOLUMES
Natural killer (NK) activity was investigated in 61 patients with Stage I11 and IV Hodgkin's disease during the course of disease and in 30 healthy age-and sex-matched healthy volunteers. The mean NK activity was significantly lower (P < 0.001) in untreated patients and in patients in the active pha
Therapy with recombinant interleukin-2 (rIL-2) induces clinical response in a significant number of patients with refractory malignant disease. Very few patients with non-Hodgkin's lymphoma (NHL) have been treated with rIL-2. The present study sought to determine if peripheral blood mononuclear cell